BYNFEZIA PEN

GrowthPeptide

octreotide acetate

NDASUBCUTANEOUSSOLUTION
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
9

Mechanism of Action

(octreotide acetate) exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of GH, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses luteinizing hormone (LH) response to gonadotropin releasing hormone (GnRH),…

Clinical Trials (5)

NCT00376064Phase 4Completed

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Started Mar 2006
20 enrolled
Acromegaly
NCT00372697Phase 3Completed

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

Started Dec 2005
28 enrolled
Acromegaly
NCT00248157Phase 3Terminated

Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

Started Nov 2005
105 enrolled
Diabetic Retinopathy
NCT00248131Phase 3Terminated

Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

Started Nov 2005
260 enrolled
Diabetic Retinopathy
NCT00166725Phase 2Completed

Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients

Started Feb 2004
40 enrolled
Prostate Cancer

Loss of Exclusivity

LOE Date
Dec 29, 2041
192 months away
Patent Expiry
Dec 29, 2041

Patent Records (5)

Patent #ExpiryTypeUse Code
10342850
May 15, 2038
Product
11052196
Nov 3, 2040
U-4009
11246991
Nov 3, 2040
U-4009
11534553
Nov 3, 2040
U-4009
12350475
Dec 29, 2041
U-4009